NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NorthStrive Biosciences amended a licensing agreement with MOA Life Plus to develop dual myostatin assets for muscle preservation in combination with GLP-1 treatments. The agreement does not indicate any direct cybersecurity vulnerabilities, but biotech partnerships may introduce supply chain, data integrity, or intellectual property risks. Affected stakeholders include NorthStrive Biosciences, MOA Life Plus, and their partners in clinical trials or manufacturing.